Last edition
News about "SERENA-6 trial"
AstraZeneca's Camizestrant Nears EU Approval for Advanced Breast Cancer Treatment
AstraZeneca moves closer to bringing camizestrant to patients in Europe after the therapy received a positive recommendation from the EMA’s committee, with trial data highlighting its potential to delay disease progression and improve outcomes in advanced breast cancer treatment.
SERENA-6 Trial | 25/05/2026 | By News Bureau
Camizestrant Plus CDK4/6 Inhibitor Recommended for EU Approval in Advanced ER-Positive Breast Cancer
Camizestrant plus a CDK4/6 inhibitor receives CHMP recommendation for EU approval in first-line advanced ER-positive breast cancer, supported by phase 3 SERENA-6 trial results showing a 56 percent reduction in disease progression or death.
SERENA-6 Trial | 25/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy